ClinicalTrials.gg
TerminatedNCT04128696INDUCE-3Updated Jul 10, 2024Results posted

Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

A Phase 3 interventional study of feladilimab and Pembrolizumab in Neoplasms, Head and Neck, sponsored by GlaxoSmithKline. Terminated at 164 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-10.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Why this study was terminated
The trial was stopped by the sponsor based on assessment of the clinical data

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
315
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 47 studies in Head and Neck Neoplasms with a site in Japan — 6 open to participants now, 19 under way, 6 of them phase 3. Head and Neck Neoplasms · Japan.

Enrollment
21st of 45
315 · median 223
Started
2019
with 3 others
Phase 3
17 of 47
1 open now
Registered
28th of 47
by date
Lead sponsor
4 of 47
GlaxoSmithKline

Among the 47 studies in Head and Neck Neoplasms with a site in Japan, this one is the 21st largest by enrollment of the 45 interventional ones that give a count, is one of 4 that started in 2019, is one of 17 in phase 3, and was the 28th registered.

Head and Neck Neoplasms

2,714 studies on the registry are indexed under Head and Neck Neoplasms; 596 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

6 of the 47 studies in Head and Neck Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 453 Head and Neck Neoplasms studies recruiting now, 345 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 21 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Head and Neck Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

The purpose of study is to evaluate if the addition of GSK3359609 to pembrolizumab as first-line treatment improves the efficacy of pembrolizumab in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma/cancer (HNSCC).This is a randomized, double-blind, adaptive Phase II/III study comparing a combination of GSK3359609 inducible T cell co-stimulatory receptor (ICOS) agonist and pembrolizumab to pembrolizumab plus placebo in participants with programmed death receptor 1-ligand 1 (PD-L1) combined positive score (CPS) >=1 R/M HNSCC.

03

Conditions studied

  • Neoplasms, Head and Neck

Keywords

  • GSK3359609
  • Pembrolizumab
  • Programmed death receptor 1-ligand 1
  • Head and neck squamous cell carcinoma/cancer
  • Inducible T cell co-stimulatory receptor
  • Keynote-A01
  • Head & neck
  • Phase III
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving signed
  • Male or female, age >=18 years
  • Histological or cytological documentation of Head and Neck Squamous Cell Carcinoma (HNSCC) that is considered incurable by local therapies
  • Primary tumor location of the oral cavity, oropharynx, hypopharynx or larynx
  • No prior systemic therapy administered in the recurrent or setting (except for systemic therapy given as part of multimodal treatment for locally advanced disease)
  • per version 1.1 guidelines
  • Performance PS score of 0 or 1
  • Adequate organ function
  • of at least 12 weeks
  • Female participants: must not be pregnant, not breastfeeding, and at least one of the following conditions apply:

    1. Not a woman of (WOCBP)
    2. A WOCBP who agrees to use a method of from 30 days prior to randomization and for at least 120 days after the last dose of study treatment
  • Male participants with female partners of child-bearing potential: must agree to use a highly effective contraception while receiving study treatment and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period
  • Provide tumor tissue from excisional or core (fine needle aspirates and bone biopsies are not acceptable) acquired within 2 years prior to randomization for immunohistochemistry (IHC) testing by central laboratory
  • Have PD-L1 Immunohistochemistry (IHC) CPS 1 status by central laboratory testing
  • Have results from testing of Human Papilloma Virus (HPV) status for oropharyngeal cancer

Exclusion criteria

Exclusion Criteria:

  • Prior therapy with an /L1/L2 and/or anti-ICOS directed agent
  • Systemic approved or anticancer therapy within 30 days or 5 half-lives of the drug, whichever is shorter
  • Major surgery 28 days prior to randomization
  • Has high risk of bleeding
  • Toxicity related to prior treatment that has not resolved to \<=Grade 1 (except alopecia, hearing loss, endocrinopathy managed with replacement therapy, and peripheral neuropathy which must be\<= Grade 2)
  • Received transfusion of blood products or administration of colony stimulating factors within 14 days prior to randomization
  • Central nervous system (CNS) , with the following exception: Participants with asymptomatic who are clinically stable and have no requirement for for at least 14 days prior to randomization
  • Invasive or history of invasive malignancy other than disease under study within the last 3 years, except as noted below:

    a. Any other invasive malignancy for which the participant was definitively treated, has been disease-free for 3 years and in the opinion of the principal investigator and GSK Medical Monitor will not affect the evaluation of the effects of the study treatment on the currently targeted malignancy, may be included in this clinical study

  • disease or syndrome that required systemic treatment within the past 2 years
  • Has a diagnosis of immunodeficiency or is receiving systemic steroids (≥10 mg oral prednisone per day or equivalent) or other agents within 7 days prior to randomization
  • Receipt of any within 30 days prior randomization
  • Prior allogeneic/autologous bone marrow or solid organ transplantation
  • Has current pneumonitis or history of non-infectious pneumonitis that required steroids or other immunosuppressive agents
  • Recent history (within the past 6 months) of uncontrolled symptomatic ascites, pleural or pericardial effusions
  • Recent history (within the past 6 months) of gastrointestinal obstruction that required surgery, acute diverticulitis, inflammatory bowel disease, or intra-abdominal abscess
  • Recent history of allergen desensitization therapy within 4 weeks of randomization
  • History or evidence of cardiac abnormalities within the 6 months prior to randomization
  • Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice
  • Active infection requiring systemic therapy
  • Known infection, or positive test for active infection (presence of hepatitis B surface antigen), or active infection
  • History of severe to monoclonal antibodies or any ingredient used in the study treatment formulations
  • Known history of active tuberculosis
  • Any serious and/or unstable pre-existing medical (aside from malignancy), psychiatric disorder, or other condition that could interfere with participant's safety, obtaining , or compliance to the study procedures in the opinion of the investigator
  • Is currently participating in (unless in follow-up phase and 4 weeks have elapsed from last dose of prior investigational agent), or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to date of randomization
  • Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
315 participants (actual)

Study arms

  • Experimental
    Participants receiving feladilimab and pembrolizumab

    Participants were administered feladilimab (humanized anti-ICOS immunoglobulin G4 \[IgG4\] monoclonal antibody \[mAb\]) and pembrolizumab (humanized anti-PD-1 IgG4 mAb) as an intravenous (IV) infusion once every three weeks.

    Drug: feladilimab · Drug: Pembrolizumab

  • Active comparator
    Participants receiving placebo and pembrolizumab

    Participants were administered placebo and pembrolizumab (humanized anti-PD-1 IgG4 mAb) as an IV infusion once every three weeks.

    Drug: Pembrolizumab · Drug: Placebo

Interventions

  • feladilimab is available as an intravenous infusion.

  • Pembrolizumab is available as an intravenous infusion.

  • DrugPlacebo

    Placebo is available as an intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS) in the Programmed Death Receptor-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 Population

    OS was defined as the time from the date of randomization to the date of death due to any cause. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells. Kaplan-Meier estimate for the median OS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.

    Time frame: Up to approximately 16 months

  2. OS in the PD-L1 Expression High (CPS ≥20) Population

    OS was defined as the time from the date of randomization to the date of death due to any cause. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells. Kaplan-Meier estimate for the median OS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.

    Time frame: Up to approximately 16 months

  3. Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) in the PD-L1 CPS ≥1 Population

    PFS per RECIST version (v)1.1 was defined as the time from the date of randomization to the date of first documented disease progression or death due to any cause, whichever occurs first. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells. Kaplan-Meier estimate for the median PFS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.

    Time frame: Up to approximately 16 months

Secondary outcomes

  1. PFS Per Immune-based RECIST (iRECIST) in the PD-L1 CPS ≥1 Population

    PFS per iRECIST was defined as the interval of time from the date of randomization to the date of the first documented disease progression confirmed consecutively per iRECIST based on investigator assessment, or death due to any cause, whichever occurs first. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells. Kaplan-Meier estimate for the median PFS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.

    Time frame: Up to approximately 16 months

  2. PFS Per RECIST in the PD-L1 CPS ≥20 Population

    PFS per RECIST v1.1 was defined as the time from the date of randomization to the date of first documented disease progression per RECIST v1.1. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells. Kaplan-Meier estimate for the median PFS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.

    Time frame: Up to approximately 16 months

  3. PFS Per iRECIST (iPFS) in the PD-L1 CPS ≥20 Population

    PFS per iRECIST was defined as the interval of time from the date of randomization to the date of the first documented disease progression confirmed consecutively per iRECIST based on investigator assessment, or death due to any cause, whichever occurs first. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells. Kaplan-Meier estimate for the median PFS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.

    Time frame: Up to approximately 16 months

  4. Milestone OS Rate at 12 Months in the PD-L1 CPS ≥1 Population

    Milestone OS rate at 12 months was estimated using the Kaplan-Meier method. Associated 95% confidence intervals are estimated using the Brookmeyer-Crowley method. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

    Time frame: 12 months

  5. Milestone OS Rate at 24 Months in the PD-L1 CPS ≥1 Population

    Milestone OS rate at 24 months was not evaluated. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

    Time frame: 24 months

  6. Milestone OS Rate at 12 Months in the PD-L1 CPS ≥20 Population

    Milestone OS rate at 12 months was estimated using the Kaplan-Meier method. Associated 95% confidence intervals are estimated using the Brookmeyer-Crowley method. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

    Time frame: 12 months

  7. Milestone OS Rate at 24 Months in the PD-L1 CPS ≥20 Population

    Milestone OS rate at 24 months was not evaluated. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

    Time frame: 24 months

  8. Overall Response Rate (ORR) Per RECIST v1.1 in the PD-L1 CPS ≥1 Population

    ORR per RECIST v1.1 was defined as the proportion of the participants who have a complete response (CR) or partial response (PR) as the best overall response per RECIST v1.1 based upon investigator assessment. As a randomized double-blind study in which primary endpoints are OS and PFS, the confirmation of CR and PR was not required. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

    Time frame: Up to approximately 16 months

  9. ORR Per RECIST v1.1 in the PD-L1 CPS ≥20 Population

    ORR per RECIST v1.1 was defined as the proportion of the participants who have a CR or PR as the best overall response per RECIST v1.1 based upon investigator assessment. As a randomized double-blind study in which primary endpoints are OS and PFS, the confirmation of CR and PR was not required. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

    Time frame: Up to approximately 16 months

  10. Disease Control Rate (DCR) Per RECIST v1.1 in the PD-L1 CPS ≥1 Population

    DCR per RECIST v1.1 based upon investigator assessment, was defined as the percentage of participants with a best overall response of CR or PR at any time plus stable disease (SD) meeting the minimum time of 15 weeks. A status of SD≥15 weeks will be assigned if the follow-up disease assessment has met the SD criteria at least once after the date of randomization at a minimum of 14 weeks (98 days) considering a one-week visit window. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

    Time frame: Up to approximately 16 months

  11. DCR Per RECIST v1.1 in the PD-L1 CPS ≥20 Population

    DCR per RECIST v1.1 based upon investigator assessment, was defined as the percentage of participants with a best overall response of CR or PR at any time plus stable disease (SD) meeting the minimum time of 15 weeks. A status of SD≥15 weeks will be assigned if the follow-up disease assessment has met the SD criteria at least once after the date of randomization at a minimum of 14 weeks (98 days) considering a one-week visit window. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

    Time frame: Up to approximately 16 months

  12. Duration of Response (DoR) Per RECIST v1.1 in the PD-L1 CPS ≥1 Population

    DoR per RECIST v1.1 is defined as the time from first documented evidence of CR or PR until first documented disease progression per RECIST v1.1 based upon investigator assessment or death due to any cause, whichever occurs first, among participants who demonstrated CR or PR as the best overall response per RECIST v1.1. Kaplan-Meier estimate for the median DoR is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

    Time frame: Up to approximately 16 months

  13. DoR Per RECIST v1.1 in the PD-L1 CPS ≥20 Population

    DoR per RECIST v1.1 is defined as the time from first documented evidence of CR or PR until first documented disease progression per RECIST v1.1 based upon investigator assessment or death due to any cause, whichever occurs first, among participants who demonstrated CR or PR as the best overall response per RECIST v1.1. Kaplan-Meier estimate for the median DoR is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

    Time frame: Up to approximately 16 months

  14. Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, any other situation such as important medical events according to medical or scientific judgement.

    Time frame: Up to approximately 43 months

  15. Number of Participants With AEs by Severity

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Severity of each AE was reported during the study and was assigned a grade according to the National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE). AEs severity were graded on a 5-point scale as: 1 = mild; discomfort noticed, but no disruption to daily activity, 2 = moderate; discomfort sufficient to reduce or affect normal daily activity, 3 = severe; inability to work or perform normal daily activity, 4 = life-threatening consequences and 5 = death related to AE.

    Time frame: Up to approximately 43 months

  16. Number of Participants With SAEs by Severity

    An SAE was defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, any other situation such as important medical events according to medical or scientific judgement. Severity of each SAE was reported during the study and was assigned a grade according to the NCI-CTCAE. SAEs severity were graded on a 5-point scale as: 1 = mild; discomfort noticed, but no disruption to daily activity, 2 = moderate; discomfort sufficient to reduce or affect normal daily activity, 3 = severe; inability to work or perform normal daily activity, 4 = life-threatening consequences and 5 = death related to AE. Data of participants experiencing SAEs of Grade ≥3 have been presented.

    Time frame: Up to approximately 43 months

  17. Number of Participants With Adverse Events of Special Interest (AESI)

    AESI were defined as events of potential immunologic etiology, including immune-related AEs (irAEs). Such events recently reported after treatment with other immune modulatory therapy include colitis, uveitis, hepatitis, pneumonitis, diarrhea, endocrine disorders, and specific cutaneous toxicities, as well as other events that may be immune mediated.

    Time frame: Up to approximately 43 months

  18. Number of Participants With AESI by Severity

    AESI were defined as events of potential immunologic etiology, including immune-related AEs (irAEs). Such events recently reported after treatment with other immune modulatory therapy include colitis, uveitis, hepatitis, pneumonitis, diarrhea, endocrine disorders, and specific cutaneous toxicities, as well as other events that may be immune mediated. Severity of each AESI was reported during the study and was assigned a grade according to the NCI-CTCAE. AESIs severity were graded on a 5-point scale as: 1 = mild; discomfort noticed, but no disruption to daily activity, 2 = moderate; discomfort sufficient to reduce or affect normal daily activity, 3 = severe; inability to work or perform normal daily activity, 4 = life-threatening consequences and 5 = death related to AE. Data of participants experiencing AESIs of Grade ≥3 have been presented.

    Time frame: Up to approximately 43 months

  19. Number of Participants With Dose Modifications

    Number of participants with dose modifications (including dose interruptions, dose delays and treatment discontinuations) were reported by each interventional component.

    Time frame: Up to approximately 16 months

  20. Time to Deterioration (TTD) in Pain in the PD-L1 CPS ≥1 Population

    TTD in pain is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the European Organization for Research and Treatment of Cancer Item Library(EORTC IL51) pain domain, i.e. an increase from baseline of at least 8.33 observed at all subsequent non-missing visits. The EORTC Quality of Life Questionnaire 35-Item Head and Neck Module (QLQ-H\&N35) is a head and neck specific module with multi-item scales. The questionnaire scores for each scale and single-item measure are averaged and transformed linearly to present a score ranging from 0-100. A high score represents a high/healthy level of functioning. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

    Time frame: Up to approximately 16 months

  21. TTD in Pain in the PD-L1 CPS ≥20 Population

    TTD in pain is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the EORTC IL51 pain domain, i.e. an increase from baseline of at least 8.33 observed at all subsequent non-missing visits. The EORTC QLQ-H\&N35 is a head and neck specific module with multi-item scales. The mouth pain, swallowing, speech problems, opening mouth, coughing, feeding tube, and trouble with social eating domains were administered and referred to as the EORTC IL51. The questionnaire scores for each scale and single-item measure are averaged and transformed linearly to present a score ranging from 0-100. A high score represents a high/healthy level of functioning. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

    Time frame: Up to approximately 16 months

  22. TTD in Physical Function in the PD-L1 CPS ≥1 Population

    TTD in physical function is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the PF T-score, i.e. a decrease from baseline of at least 2.4 observed at all subsequent non-missing visits, as measured by the PROMIS PF 8c. The PROMIS PF 8c is an 8-item fixed length short form derived from the PROMIS Physical Function item bank. It includes a 5-point scale with three sets of response options. Scores on the PROMIS PF 8c are reported on a T score metric (mean = 50 and SD = 10), with higher scores reflecting better physical functioning. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

    Time frame: Up to approximately 16 months

  23. TTD in Physical Function in the PD-L1 CPS ≥20 Population

    TTD in physical function is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the PF T-score, i.e. a decrease from baseline of at least 2.4 observed at all subsequent non-missing visits, as measured by the PROMIS PF 8c. The PROMIS PF 8c is an 8-item fixed length short form derived from the PROMIS Physical Function item bank. It includes a 5-point scale with three sets of response options. Scores on the PROMIS PF 8c are reported on a T score metric (mean = 50 and SD = 10), with higher scores reflecting better physical functioning. Data are presented for the PD-L1 CPS \>=1 participants from mITT population. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

    Time frame: Up to approximately 16 months

07

Results

Posted May 24, 2022

Participant flow

A total of 315 participants with recurrent or metastatic head and neck squamous cell carcinoma/cancer (HNSCC) were enrolled in this study.

Participant flow — Overall Study
MilestoneParticipants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and Pembrolizumab
Started158157
Modified intent to treat (mitt) population157156
Safety population159156
Completed11598
Not completed4359
Withdrew: Lost to follow-up37
Withdrew: Withdrawal by subject1211
Withdrew: Study closed/terminated2638
Withdrew: Physician decision23

Outcome measures

PrimaryOverall Survival (OS) in the Programmed Death Receptor-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 Population

OS was defined as the time from the date of randomization to the date of death due to any cause. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells. Kaplan-Meier estimate for the median OS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.

Time frame:
Up to approximately 16 months
Reported as:
Median · Week
Overall Survival (OS) in the Programmed Death Receptor-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 Population
WeekParticipants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and Pembrolizumab
Overall Survival (OS) in the Programmed Death Receptor-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 Population44.1 (35.9 to NA)NA (52.4 to NA)
Statistical analysis
  • Participants Receiving Feladilimab and Pembrolizumab vs Participants Receiving Placebo and Pembrolizumab · Stratified Cox proportional hazard model · p = 0.973 (Nominal p-value was calculated based on the one-sided log-rank test, stratified by PD-L1 expression (CPS ≥20 vs. 1≤ CPS \<20) and HPV status (oropharynx HPV positive vs oropharynx HPV negative/unknown and non-oropharynx).) · Hazard ratio (hr): 1.51 · 95% CI 0.99 to 2.29
PrimaryOS in the PD-L1 Expression High (CPS ≥20) Population

OS was defined as the time from the date of randomization to the date of death due to any cause. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells. Kaplan-Meier estimate for the median OS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.

Time frame:
Up to approximately 16 months
Reported as:
Median · Week
OS in the PD-L1 Expression High (CPS ≥20) Population
WeekParticipants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and Pembrolizumab
OS in the PD-L1 Expression High (CPS ≥20) Population42.1 (25.4 to NA)NA (52.4 to NA)
Statistical analysis
  • Participants Receiving Feladilimab and Pembrolizumab vs Participants Receiving Placebo and Pembrolizumab · Stratified Cox proportional hazard model · p = >0.999 (Nominal p-value was calculated based on the one-sided log-rank test, stratified by HPV status (oropharynx HPV positive vs oropharynx HPV negative/unknown and non-oropharynx).) · Hazard ratio (hr): 4.44 · 95% CI 2.01 to 9.82
PrimaryProgression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) in the PD-L1 CPS ≥1 Population

PFS per RECIST version (v)1.1 was defined as the time from the date of randomization to the date of first documented disease progression or death due to any cause, whichever occurs first. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells. Kaplan-Meier estimate for the median PFS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.

Time frame:
Up to approximately 16 months
Reported as:
Median · Week
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) in the PD-L1 CPS ≥1 Population
WeekParticipants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and Pembrolizumab
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) in the PD-L1 CPS ≥1 Population10.1 (9.1 to 15.0)16.0 (14.3 to 26.1)
Statistical analysis
  • Participants Receiving Feladilimab and Pembrolizumab vs Participants Receiving Placebo and Pembrolizumab · Stratified Cox proportional hazard model · p = 0.989 (Nominal p-value was calculated based on the log-rank test, stratified by stratified by PD-L1 expression (CPS ≥20 vs. 1≤ CPS \<20) and HPV status (oropharynx HPV positive vs oropharynx HPV negative/unknown and non-oropharynx).) · Hazard ratio (hr): 1.40 · 95% CI 1.05 to 1.86
SecondaryPFS Per Immune-based RECIST (iRECIST) in the PD-L1 CPS ≥1 Population

PFS per iRECIST was defined as the interval of time from the date of randomization to the date of the first documented disease progression confirmed consecutively per iRECIST based on investigator assessment, or death due to any cause, whichever occurs first. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells. Kaplan-Meier estimate for the median PFS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.

Time frame:
Up to approximately 16 months
Reported as:
Median · Week
PFS Per Immune-based RECIST (iRECIST) in the PD-L1 CPS ≥1 Population
WeekParticipants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and Pembrolizumab
PFS Per Immune-based RECIST (iRECIST) in the PD-L1 CPS ≥1 Population13.0 (9.1 to 15.1)21.4 (15.6 to 27.0)
Statistical analysis
  • Participants Receiving Feladilimab and Pembrolizumab vs Participants Receiving Placebo and Pembrolizumab · Stratified Cox proportional hazard model · p = 0.996 (Nominal p-value was calculated based on the log-rank test, stratified by PD-L1 expression (CPS ≥20 vs. 1≤ CPS \<20) and HPV status (oropharynx HPV positive vs oropharynx HPV negative/unknown and non-oropharynx).) · Hazard ratio (hr): 1.48 · 95% CI 1.10 to 1.99
SecondaryPFS Per RECIST in the PD-L1 CPS ≥20 Population

PFS per RECIST v1.1 was defined as the time from the date of randomization to the date of first documented disease progression per RECIST v1.1. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells. Kaplan-Meier estimate for the median PFS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.

Time frame:
Up to approximately 16 months
Reported as:
Median · Week
PFS Per RECIST in the PD-L1 CPS ≥20 Population
WeekParticipants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and Pembrolizumab
PFS Per RECIST in the PD-L1 CPS ≥20 Population13.0 (8.6 to 26.1)21.1 (15.6 to 32.9)
Statistical analysis
  • Participants Receiving Feladilimab and Pembrolizumab vs Participants Receiving Placebo and Pembrolizumab · Stratified Cox proportional hazard model · Hazard ratio (hr): 1.55 · 95% CI 0.98 to 2.43
SecondaryPFS Per iRECIST (iPFS) in the PD-L1 CPS ≥20 Population

PFS per iRECIST was defined as the interval of time from the date of randomization to the date of the first documented disease progression confirmed consecutively per iRECIST based on investigator assessment, or death due to any cause, whichever occurs first. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells. Kaplan-Meier estimate for the median PFS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.

Time frame:
Up to approximately 16 months
Reported as:
Median · Week
PFS Per iRECIST (iPFS) in the PD-L1 CPS ≥20 Population
WeekParticipants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and Pembrolizumab
PFS Per iRECIST (iPFS) in the PD-L1 CPS ≥20 Population13.1 (8.6 to 26.7)26.7 (20.1 to 32.9)
Statistical analysis
  • Participants Receiving Feladilimab and Pembrolizumab vs Participants Receiving Placebo and Pembrolizumab · Stratified Cox proportional hazard model · Hazard ratio (hr): 1.59 · 95% CI 1.00 to 2.53
SecondaryMilestone OS Rate at 12 Months in the PD-L1 CPS ≥1 Population

Milestone OS rate at 12 months was estimated using the Kaplan-Meier method. Associated 95% confidence intervals are estimated using the Brookmeyer-Crowley method. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

Time frame:
12 months
Reported as:
Number · Percentage of participants
Milestone OS Rate at 12 Months in the PD-L1 CPS ≥1 Population
Percentage of participantsParticipants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and Pembrolizumab
Milestone OS Rate at 12 Months in the PD-L1 CPS ≥1 Population44.0 (30.0 to 58.0)68.0 (57.0 to 77.0)
SecondaryMilestone OS Rate at 24 Months in the PD-L1 CPS ≥1 Population

Milestone OS rate at 24 months was not evaluated. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

Time frame:
24 months

No measurements were reported for this outcome.

SecondaryMilestone OS Rate at 12 Months in the PD-L1 CPS ≥20 Population

Milestone OS rate at 12 months was estimated using the Kaplan-Meier method. Associated 95% confidence intervals are estimated using the Brookmeyer-Crowley method. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

Time frame:
12 months
Reported as:
Number · Percentage of participants
Milestone OS Rate at 12 Months in the PD-L1 CPS ≥20 Population
Percentage of participantsParticipants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and Pembrolizumab
Milestone OS Rate at 12 Months in the PD-L1 CPS ≥20 Population46.0 (28.0 to 63.0)88.0 (76.0 to 94.0)
SecondaryMilestone OS Rate at 24 Months in the PD-L1 CPS ≥20 Population

Milestone OS rate at 24 months was not evaluated. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

Time frame:
24 months

No measurements were reported for this outcome.

SecondaryOverall Response Rate (ORR) Per RECIST v1.1 in the PD-L1 CPS ≥1 Population

ORR per RECIST v1.1 was defined as the proportion of the participants who have a complete response (CR) or partial response (PR) as the best overall response per RECIST v1.1 based upon investigator assessment. As a randomized double-blind study in which primary endpoints are OS and PFS, the confirmation of CR and PR was not required. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

Time frame:
Up to approximately 16 months
Reported as:
Number · Percentage of Participants
Overall Response Rate (ORR) Per RECIST v1.1 in the PD-L1 CPS ≥1 Population
Percentage of ParticipantsParticipants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and Pembrolizumab
Overall Response Rate (ORR) Per RECIST v1.1 in the PD-L1 CPS ≥1 Population19.7 (13.8 to 26.8)25.0 (18.4 to 32.6)
Statistical analysis
  • Participants Receiving Feladilimab and Pembrolizumab vs Participants Receiving Placebo and Pembrolizumab · Difference in percentage: -5.3 · 95% CI -14.6 to 4.0
SecondaryORR Per RECIST v1.1 in the PD-L1 CPS ≥20 Population

ORR per RECIST v1.1 was defined as the proportion of the participants who have a CR or PR as the best overall response per RECIST v1.1 based upon investigator assessment. As a randomized double-blind study in which primary endpoints are OS and PFS, the confirmation of CR and PR was not required. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

Time frame:
Up to approximately 16 months
Reported as:
Number · Percentage of Participants
ORR Per RECIST v1.1 in the PD-L1 CPS ≥20 Population
Percentage of ParticipantsParticipants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and Pembrolizumab
ORR Per RECIST v1.1 in the PD-L1 CPS ≥20 Population20.0 (11.4 to 31.3)33.3 (22.4 to 45.7)
Statistical analysis
  • Participants Receiving Feladilimab and Pembrolizumab vs Participants Receiving Placebo and Pembrolizumab · Difference in percentage: -13.3 · 95% CI -27.8 to 1.5
SecondaryDisease Control Rate (DCR) Per RECIST v1.1 in the PD-L1 CPS ≥1 Population

DCR per RECIST v1.1 based upon investigator assessment, was defined as the percentage of participants with a best overall response of CR or PR at any time plus stable disease (SD) meeting the minimum time of 15 weeks. A status of SD≥15 weeks will be assigned if the follow-up disease assessment has met the SD criteria at least once after the date of randomization at a minimum of 14 weeks (98 days) considering a one-week visit window. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

Time frame:
Up to approximately 16 months
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR) Per RECIST v1.1 in the PD-L1 CPS ≥1 Population
Percentage of ParticipantsParticipants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and Pembrolizumab
Disease Control Rate (DCR) Per RECIST v1.1 in the PD-L1 CPS ≥1 Population33.1 (25.8 to 41.1)44.9 (36.9 to 53.0)
Statistical analysis
  • Participants Receiving Feladilimab and Pembrolizumab vs Participants Receiving Placebo and Pembrolizumab · Difference in percentage: -11.8 · 95% CI -22.4 to -1.1
SecondaryDCR Per RECIST v1.1 in the PD-L1 CPS ≥20 Population

DCR per RECIST v1.1 based upon investigator assessment, was defined as the percentage of participants with a best overall response of CR or PR at any time plus stable disease (SD) meeting the minimum time of 15 weeks. A status of SD≥15 weeks will be assigned if the follow-up disease assessment has met the SD criteria at least once after the date of randomization at a minimum of 14 weeks (98 days) considering a one-week visit window. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

Time frame:
Up to approximately 16 months
Reported as:
Number · Percentage of Participants
DCR Per RECIST v1.1 in the PD-L1 CPS ≥20 Population
Percentage of ParticipantsParticipants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and Pembrolizumab
DCR Per RECIST v1.1 in the PD-L1 CPS ≥20 Population37.1 (25.9 to 49.5)55.1 (42.6 to 67.1)
Statistical analysis
  • Participants Receiving Feladilimab and Pembrolizumab vs Participants Receiving Placebo and Pembrolizumab · Difference in percentage: -18.0 · 95% CI -33.7 to -1.4
SecondaryDuration of Response (DoR) Per RECIST v1.1 in the PD-L1 CPS ≥1 Population

DoR per RECIST v1.1 is defined as the time from first documented evidence of CR or PR until first documented disease progression per RECIST v1.1 based upon investigator assessment or death due to any cause, whichever occurs first, among participants who demonstrated CR or PR as the best overall response per RECIST v1.1. Kaplan-Meier estimate for the median DoR is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

Time frame:
Up to approximately 16 months
Reported as:
Median · Weeks
Duration of Response (DoR) Per RECIST v1.1 in the PD-L1 CPS ≥1 Population
WeeksParticipants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and Pembrolizumab
Duration of Response (DoR) Per RECIST v1.1 in the PD-L1 CPS ≥1 PopulationNA (NA to NA)NA (20.6 to NA)
SecondaryDoR Per RECIST v1.1 in the PD-L1 CPS ≥20 Population

DoR per RECIST v1.1 is defined as the time from first documented evidence of CR or PR until first documented disease progression per RECIST v1.1 based upon investigator assessment or death due to any cause, whichever occurs first, among participants who demonstrated CR or PR as the best overall response per RECIST v1.1. Kaplan-Meier estimate for the median DoR is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

Time frame:
Up to approximately 16 months
Reported as:
Median · Weeks
DoR Per RECIST v1.1 in the PD-L1 CPS ≥20 Population
WeeksParticipants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and Pembrolizumab
DoR Per RECIST v1.1 in the PD-L1 CPS ≥20 PopulationNA (18.1 to NA)NA (12.1 to NA)
SecondaryNumber of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, any other situation such as important medical events according to medical or scientific judgement.

Time frame:
Up to approximately 43 months
Reported as:
Count of participants · Participants
Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsParticipants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and Pembrolizumab
Any AE150145
Any SAE5253
SecondaryNumber of Participants With AEs by Severity

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Severity of each AE was reported during the study and was assigned a grade according to the National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE). AEs severity were graded on a 5-point scale as: 1 = mild; discomfort noticed, but no disruption to daily activity, 2 = moderate; discomfort sufficient to reduce or affect normal daily activity, 3 = severe; inability to work or perform normal daily activity, 4 = life-threatening consequences and 5 = death related to AE.

Time frame:
Up to approximately 43 months
Reported as:
Count of participants · Participants
Number of Participants With AEs by Severity
ParticipantsParticipants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and Pembrolizumab
Grade 13421
Grade 24854
Grade 34646
Grade 476
Grade 51518
SecondaryNumber of Participants With SAEs by Severity

An SAE was defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, any other situation such as important medical events according to medical or scientific judgement. Severity of each SAE was reported during the study and was assigned a grade according to the NCI-CTCAE. SAEs severity were graded on a 5-point scale as: 1 = mild; discomfort noticed, but no disruption to daily activity, 2 = moderate; discomfort sufficient to reduce or affect normal daily activity, 3 = severe; inability to work or perform normal daily activity, 4 = life-threatening consequences and 5 = death related to AE. Data of participants experiencing SAEs of Grade ≥3 have been presented.

Time frame:
Up to approximately 43 months
Reported as:
Count of participants · Participants
Number of Participants With SAEs by Severity
ParticipantsParticipants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and Pembrolizumab
Number of Participants With SAEs by Severity4346
SecondaryNumber of Participants With Adverse Events of Special Interest (AESI)

AESI were defined as events of potential immunologic etiology, including immune-related AEs (irAEs). Such events recently reported after treatment with other immune modulatory therapy include colitis, uveitis, hepatitis, pneumonitis, diarrhea, endocrine disorders, and specific cutaneous toxicities, as well as other events that may be immune mediated.

Time frame:
Up to approximately 43 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events of Special Interest (AESI)
ParticipantsParticipants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and Pembrolizumab
Number of Participants With Adverse Events of Special Interest (AESI)4967
SecondaryNumber of Participants With AESI by Severity

AESI were defined as events of potential immunologic etiology, including immune-related AEs (irAEs). Such events recently reported after treatment with other immune modulatory therapy include colitis, uveitis, hepatitis, pneumonitis, diarrhea, endocrine disorders, and specific cutaneous toxicities, as well as other events that may be immune mediated. Severity of each AESI was reported during the study and was assigned a grade according to the NCI-CTCAE. AESIs severity were graded on a 5-point scale as: 1 = mild; discomfort noticed, but no disruption to daily activity, 2 = moderate; discomfort sufficient to reduce or affect normal daily activity, 3 = severe; inability to work or perform normal daily activity, 4 = life-threatening consequences and 5 = death related to AE. Data of participants experiencing AESIs of Grade ≥3 have been presented.

Time frame:
Up to approximately 43 months
Reported as:
Count of participants · Participants
Number of Participants With AESI by Severity
ParticipantsParticipants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and Pembrolizumab
Number of Participants With AESI by Severity26
SecondaryNumber of Participants With Dose Modifications

Number of participants with dose modifications (including dose interruptions, dose delays and treatment discontinuations) were reported by each interventional component.

Time frame:
Up to approximately 16 months
Reported as:
Count of participants · Participants
Number of Participants With Dose Modifications
ParticipantsParticipants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and Pembrolizumab
Dose interruption by component - feladilimab4NA
Dose interruption by component - placeboNA1
Dose interruption by component - pembrolizumab01
Dose delays by component - feladilimab9NA
Dose delays by component - placeboNA5
Dose delays by component - pembrolizumab116
Treatment discontinuation by component - feladilimab/placebo159154
Treatment discontinuation by component - pembrolizumab10893
SecondaryTime to Deterioration (TTD) in Pain in the PD-L1 CPS ≥1 Population

TTD in pain is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the European Organization for Research and Treatment of Cancer Item Library(EORTC IL51) pain domain, i.e. an increase from baseline of at least 8.33 observed at all subsequent non-missing visits. The EORTC Quality of Life Questionnaire 35-Item Head and Neck Module (QLQ-H\&N35) is a head and neck specific module with multi-item scales. The questionnaire scores for each scale and single-item measure are averaged and transformed linearly to present a score ranging from 0-100. A high score represents a high/healthy level of functioning. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

Time frame:
Up to approximately 16 months
Reported as:
Median · Months
Time to Deterioration (TTD) in Pain in the PD-L1 CPS ≥1 Population
MonthsParticipants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and Pembrolizumab
Time to Deterioration (TTD) in Pain in the PD-L1 CPS ≥1 Population6.3 (5.1 to NA)10.4 (6.3 to NA)
Statistical analysis
  • Participants Receiving Feladilimab and Pembrolizumab vs Participants Receiving Placebo and Pembrolizumab · Stratified Cox proportional hazard model · p = 0.783 (Nominal p-value was calculated based on the one-sided log-rank test, stratified by PD-L1 expression (CPS ≥20 vs. 1≤ CPS \<20) and HPV status (oropharynx HPV positive vs oropharynx HPV negative/unknown and non-oropharynx).) · Hazard ratio (hr): 1.17 · 95% CI 0.78 to 1.77
SecondaryTTD in Pain in the PD-L1 CPS ≥20 Population

TTD in pain is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the EORTC IL51 pain domain, i.e. an increase from baseline of at least 8.33 observed at all subsequent non-missing visits. The EORTC QLQ-H\&N35 is a head and neck specific module with multi-item scales. The mouth pain, swallowing, speech problems, opening mouth, coughing, feeding tube, and trouble with social eating domains were administered and referred to as the EORTC IL51. The questionnaire scores for each scale and single-item measure are averaged and transformed linearly to present a score ranging from 0-100. A high score represents a high/healthy level of functioning. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

Time frame:
Up to approximately 16 months
Reported as:
Median · Months
TTD in Pain in the PD-L1 CPS ≥20 Population
MonthsParticipants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and Pembrolizumab
TTD in Pain in the PD-L1 CPS ≥20 PopulationNA (5.1 to NA)12 (6.3 to NA)
Statistical analysis
  • Participants Receiving Feladilimab and Pembrolizumab vs Participants Receiving Placebo and Pembrolizumab · Stratified Cox proportional hazard model · p = 0.500 (Nominal p-value was calculated based on the log-rank test, stratified by HPV status (oropharynx HPV positive vs oropharynx HPV negative/unknown and non-oropharynx).) · Hazard ratio (hr): 1.00 · 95% CI 0.50 to 2.00
SecondaryTTD in Physical Function in the PD-L1 CPS ≥1 Population

TTD in physical function is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the PF T-score, i.e. a decrease from baseline of at least 2.4 observed at all subsequent non-missing visits, as measured by the PROMIS PF 8c. The PROMIS PF 8c is an 8-item fixed length short form derived from the PROMIS Physical Function item bank. It includes a 5-point scale with three sets of response options. Scores on the PROMIS PF 8c are reported on a T score metric (mean = 50 and SD = 10), with higher scores reflecting better physical functioning. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

Time frame:
Up to approximately 16 months
Reported as:
Median · Months
TTD in Physical Function in the PD-L1 CPS ≥1 Population
MonthsParticipants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and Pembrolizumab
TTD in Physical Function in the PD-L1 CPS ≥1 Population4.9 (3.5 to 7.7)4.9 (3.0 to 6.3)
Statistical analysis
  • Participants Receiving Feladilimab and Pembrolizumab vs Participants Receiving Placebo and Pembrolizumab · Stratified Cox proportional hazard model · p = 0.329 (Nominal p-value was calculated based on the one-sided log-rank test, stratified by PD-L1 expression (CPS ≥20 vs. 1≤ CPS \<20) and HPV status (oropharynx HPV positive vs oropharynx HPV negative/unknown and non-oropharynx).) · Hazard ratio (hr): 0.91 · 95% CI 0.62 to 1.34
SecondaryTTD in Physical Function in the PD-L1 CPS ≥20 Population

TTD in physical function is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the PF T-score, i.e. a decrease from baseline of at least 2.4 observed at all subsequent non-missing visits, as measured by the PROMIS PF 8c. The PROMIS PF 8c is an 8-item fixed length short form derived from the PROMIS Physical Function item bank. It includes a 5-point scale with three sets of response options. Scores on the PROMIS PF 8c are reported on a T score metric (mean = 50 and SD = 10), with higher scores reflecting better physical functioning. Data are presented for the PD-L1 CPS \>=1 participants from mITT population. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

Time frame:
Up to approximately 16 months
Reported as:
Median · Months
TTD in Physical Function in the PD-L1 CPS ≥20 Population
MonthsParticipants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and Pembrolizumab
TTD in Physical Function in the PD-L1 CPS ≥20 Population4.9 (2.1 to NA)4.9 (3.1 to NA)
Statistical analysis
  • Participants Receiving Feladilimab and Pembrolizumab vs Participants Receiving Placebo and Pembrolizumab · Stratified Cox proportional hazard model · p = 0.608 (Nominal p-value was calculated based on the one-sided log-rank test, stratified by HPV status (oropharynx HPV positive vs oropharynx HPV negative/unknown and non-oropharynx).) · Hazard ratio (hr): 1.09 · 95% CI 0.60 to 2.00

Adverse events

Collected over All cause mortality, non-SAEs and SAEs were collected from Day 1 to up to approximately 43 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Participants Receiving Feladilimab and Pembrolizumab116/159 (73%)52/159 (32.7%)125/159 (78.6%)
Participants Receiving Placebo and Pembrolizumab97/156 (62.2%)53/156 (34%)128/156 (82.1%)
Most frequent serious events
Showing 10 of 99
Most frequent serious events
EventParticipants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and Pembrolizumab
Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/1596/156
DysphagiaGastrointestinal disorders2/1594/156
COVID-19Infections and infestations2/1594/156
PneumoniaInfections and infestations4/1594/156
Pneumonia aspirationInfections and infestations4/1594/156
DyspnoeaRespiratory, thoracic and mediastinal disorders4/1593/156
HypercalcaemiaMetabolism and nutrition disorders2/1593/156
MalnutritionMetabolism and nutrition disorders0/1593/156
General physical health deteriorationGeneral disorders3/1591/156
SyncopeNervous system disorders3/1591/156
Most frequent other events
Showing 10 of 31
Most frequent other events
EventParticipants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and Pembrolizumab
FatigueGeneral disorders29/15929/156
Decreased appetiteMetabolism and nutrition disorders15/15928/156
Weight decreasedInvestigations20/15927/156
AnaemiaBlood and lymphatic system disorders26/15921/156
ConstipationGastrointestinal disorders22/15924/156
RashSkin and subcutaneous tissue disorders9/15921/156
DiarrhoeaGastrointestinal disorders21/15913/156
HypothyroidismEndocrine disorders20/15916/156
DyspnoeaRespiratory, thoracic and mediastinal disorders17/15919/156
NauseaGastrointestinal disorders17/15917/156

Baseline characteristics

Age, Customized
Age, Customized(Participants)Participants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and PembrolizumabTotal
18-64 years9579174
≥65-84 years6276138
≥85 years123
Sex: Female, Male
Sex: Female, Male(Participants)Participants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and PembrolizumabTotal
Female293160
Male129126255
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Participants Receiving Feladilimab and PembrolizumabParticipants Receiving Placebo and PembrolizumabTotal
Asian - Central/South Asian Heritage202
Asian - East Asian Heritage192241
Asian - Japanese Heritage12719
Black or African American426
Missing369
Mixed White Race112
Multiple101
White - Arabic/North African Heritage415
White - White/Caucasian/European Heritage111118229
Native Hawaiian or Other Pacific Islander101
08

Study locations

164 sites
  • GSK Investigational Site
    Duarte, California 91010, United States
  • GSK Investigational Site
    Washington, District of Columbia 20010, United States
  • GSK Investigational Site
    Saint Petersburg, Florida 33705, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202, United States
  • GSK Investigational Site
    Boston, Massachusetts 02215, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28204, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19111, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15232, United States
  • GSK Investigational Site
    Charleston, South Carolina 29425, United States
  • GSK Investigational Site
    Greenville, South Carolina 29607, United States
  • GSK Investigational Site
    Chattanooga, Tennessee 37404, United States
  • GSK Investigational Site
    Nashville, Tennessee 37203, United States
  • GSK Investigational Site
    Seattle, Washington 98108, United States
  • GSK Investigational Site
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1125ABD, Argentina
  • GSK Investigational Site
    La Plata, Buenos Aires 1900, Argentina
  • GSK Investigational Site
    Ciudad Autónoma de Buenos Aires, C1426ABP, Argentina
  • GSK Investigational Site
    San Juan, J5402DIL, Argentina
  • GSK Investigational Site
    Blacktown, New South Wales 2148, Australia
  • GSK Investigational Site
    St Leonards, New South Wales 2065, Australia
  • GSK Investigational Site
    Herston, Queensland 4029, Australia
  • GSK Investigational Site
    Heidelberg, Victoria 3084, Australia
  • GSK Investigational Site
    Melbourne, Victoria 3000, Australia
  • GSK Investigational Site
    Nedlands, Western Australia 6009, Australia
  • GSK Investigational Site
    Darlinghurst, 2010, Australia
  • GSK Investigational Site
    Vitória, Espírito Santo 29043-260, Brazil
  • GSK Investigational Site
    Florianopolis, Santa Catarina 88034-000, Brazil
  • GSK Investigational Site
    Barretos, São Paulo 14784-400, Brazil
  • GSK Investigational Site
    Sao Jose do Rio Preto, São Paulo 15090-000, Brazil
  • GSK Investigational Site
    Belo Horizonte, Minas Gerais, 30150-221, Brazil
  • GSK Investigational Site
    São Paulo, 01246-000, Brazil
  • GSK Investigational Site
    São Paulo, 04014-002, Brazil
  • GSK Investigational Site
    Calgary, Alberta T2N 4N2, Canada
  • GSK Investigational Site
    Edmonton, Alberta T6G 1Z2, Canada
  • GSK Investigational Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • GSK Investigational Site
    Hamilton, Ontario L8V 5C2, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 1Z5, Canada
  • GSK Investigational Site
    Montreal, Quebec H2X 3E4, Canada
  • GSK Investigational Site
    Montreal, Quebec H3T 1E2, Canada
  • GSK Investigational Site
    Quebec City, Quebec G1J 1Z4, Canada
  • GSK Investigational Site
    Rimouski, Quebec G5L 5T1, Canada
  • GSK Investigational Site
    Guangzhou, Guangdong 510060, China
  • GSK Investigational Site
    Guangzhou, Guangdong 510503, China
  • GSK Investigational Site
    Nanning, Guangxi 530021, China
  • GSK Investigational Site
    Guiyang, Guizhou 550000, China
  • GSK Investigational Site
    Wuhan, Hubei 430022, China
  • GSK Investigational Site
    Nanchang, Jiangxi 330029, China
  • GSK Investigational Site
    Chengdu, Sichuan 610000, China
  • GSK Investigational Site
    Chengdu, Sichuan 610041, China
  • GSK Investigational Site
    Bengbu, 233000, China
  • GSK Investigational Site
    Harbin, 150000, China
  • GSK Investigational Site
    Hefei, 230001, China
  • GSK Investigational Site
    Shnghai, 200126, China
  • GSK Investigational Site
    Copenhagen, DK-2100, Denmark
  • GSK Investigational Site
    Bordeaux, 33000, France
  • GSK Investigational Site
    Epagny Metz-Tessy, 74370, France
  • GSK Investigational Site
    Le Mans, 72000, France
  • GSK Investigational Site
    Lille, 59000, France
  • GSK Investigational Site
    Lyon cedex 08, 69373, France
  • GSK Investigational Site
    Paris, 75005, France
  • GSK Investigational Site
    Saint Herblain cedex, 44805, France
  • GSK Investigational Site
    Strasbourg, 67200, France
  • GSK Investigational Site
    Toulouse Cedex 9, 31059, France
  • GSK Investigational Site
    Valenciennes Cedex, 59322, France
  • GSK Investigational Site
    Ulm, Baden-Wuerttemberg 89075, Germany
  • GSK Investigational Site
    Aachen, Nordrhein-Westfalen 52074, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04103, Germany
  • GSK Investigational Site
    Berlin, 12200, Germany
  • GSK Investigational Site
    Hamburg, 20246, Germany
  • GSK Investigational Site
    Hamburg, 22087, Germany
  • GSK Investigational Site
    Heraklion,Crete, 71110, Greece
  • GSK Investigational Site
    Thessaloniki, 54622, Greece
  • GSK Investigational Site
    Thessaloniki, 54645, Greece
  • GSK Investigational Site
    Dublin, 8, Ireland
  • GSK Investigational Site
    Dublin, D09 V2N0, Ireland
  • GSK Investigational Site
    Jerusalem, 91120, Israel
  • GSK Investigational Site
    Petah Tikva, 49100, Israel
  • GSK Investigational Site
    Ramat Gan, 52621, Israel
  • GSK Investigational Site
    Meldola (FC), Emilia-Romagna 47014, Italy
  • GSK Investigational Site
    Brescia, Lombardia 25123, Italy
  • GSK Investigational Site
    Milano, Lombardia 20133, Italy
  • GSK Investigational Site
    Milano, Lombardia 20141, Italy
  • GSK Investigational Site
    Candiolo, Piemonte 10060, Italy
  • GSK Investigational Site
    Legnago (VR), Veneto 37045, Italy
  • GSK Investigational Site
    Chiba, 260-8717, Japan
  • GSK Investigational Site
    Chiba, 277-8577, Japan
  • GSK Investigational Site
    Ehime, 791-0280, Japan
  • GSK Investigational Site
    Fukuoka, 812-8582, Japan
  • GSK Investigational Site
    Hokkaido, 060-8648, Japan
  • GSK Investigational Site
    Hyogo, 673-8558, Japan
  • GSK Investigational Site
    Ibaraki, 305-8576, Japan
  • GSK Investigational Site
    Iwate, 028-3695, Japan
  • GSK Investigational Site
    Kagawa, 761-0793, Japan
  • GSK Investigational Site
    Kanagawa, 259-1143, Japan
  • GSK Investigational Site
    Miyagi, 981-1293, Japan
  • GSK Investigational Site
    Niigata, 951-8520, Japan
  • GSK Investigational Site
    Osaka, 534-0021, Japan
  • GSK Investigational Site
    Saitama, 362-0806, Japan
  • GSK Investigational Site
    Shizuoka, 411-8777, Japan
  • GSK Investigational Site
    Tokyo, 113-8431, Japan
  • GSK Investigational Site
    Tokyo, 113-8519, Japan

Showing the first 100 of 164 sites across 26 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a data sharing agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Apr 2021, 17 months.

Results were first posted in May 2022, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2019
First posted
Oct 16, 2019
StartActual
Nov 21, 2019
Primary completionActual
Apr 27, 2021
CompletionActual
Jun 20, 2023
Results first posted
May 24, 2022
Last update
Jul 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04128696
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 16, 2019
Start date
Nov 21, 2019
Primary completion
Apr 27, 2021
Completion
Jun 20, 2023
Results posted
May 24, 2022
Last update
Jul 10, 2024

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Feladilimab

Start the discussion